| Deep learning based tissue analysis predicts outcome in colorectal cancer D Bychkov, N Linder, R Turkki, S Nordling, PE Kovanen, C Verrill, ... Scientific reports 8 (1), 3395, 2018 | 753 | 2018 |
| Phase I study with ONCOS-102 for the treatment of solid tumors–an evaluation of clinical response and exploratory analyses of immune markers T Ranki, S Pesonen, A Hemminki, K Partanen, K Kairemo, T Alanko, ... Journal for immunotherapy of cancer 4 (1), 17, 2016 | 238 | 2016 |
| Identification of tumor epithelium and stroma in tissue microarrays using texture analysis N Linder, J Konsti, R Turkki, E Rahtu, M Lundin, S Nordling, C Haglund, ... Diagnostic pathology 7 (1), 22, 2012 | 209 | 2012 |
| Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis S Blom, L Paavolainen, D Bychkov, R Turkki, P Mäki-Teeri, A Hemmes, ... Scientific reports 7 (1), 15580, 2017 | 200 | 2017 |
| A Malaria Diagnostic Tool Based on Computer Vision Screening and Visualization of Plasmodium falciparum Candidate Areas in Digitized Blood Smears N Linder, R Turkki, M Walliander, A Mårtensson, V Diwan, E Rahtu, ... PloS one 9 (8), e104855, 2014 | 160 | 2014 |
| Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices EJ Davies, M Dong, M Gutekunst, K Närhi, HJAA Van Zoggel, S Blom, ... Scientific reports 5 (1), 17187, 2015 | 153 | 2015 |
| Breast cancer outcome prediction with tumour tissue images and machine learning R Turkki, D Byckhov, M Lundin, J Isola, S Nordling, PE Kovanen, C Verrill, ... Breast cancer research and treatment 177 (1), 41-52, 2019 | 149 | 2019 |
| Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples R Turkki, N Linder, PE Kovanen, T Pellinen, J Lundin Journal of pathology informatics 7 (1), 38, 2016 | 145 | 2016 |
| Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML O Brück, S Blom, O Dufva, R Turkki, H Chheda, A Ribeiro, P Kovanen, ... Leukemia 32 (7), 1643-1656, 2018 | 115 | 2018 |
| Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy O Hemminki, S Parviainen, J Juhila, R Turkki, N Linder, J Lundin, ... Oncotarget 6 (6), 4467, 2015 | 93 | 2015 |
| Label-free prediction of cell painting from brightfield images JO Cross-Zamirski, E Mouchet, G Williams, CB Schönlieb, R Turkki, ... Scientific reports 12 (1), 10001, 2022 | 82 | 2022 |
| Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival O Brück, O Dufva, H Hohtari, S Blom, R Turkki, M Ilander, P Kovanen, ... Blood advances 4 (2), 274-286, 2020 | 80 | 2020 |
| Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL H Hohtari, O Brück, S Blom, R Turkki, M Sinisalo, PE Kovanen, ... Leukemia 33 (7), 1570-1582, 2019 | 78 | 2019 |
| Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at … L Vassilev, T Ranki, T Joensuu, E Jäger, J Karbach, C Wahle, K Partanen, ... Oncoimmunology 4 (7), e1017702, 2015 | 66 | 2015 |
| Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type … T Ranki, T Joensuu, E Jäger, J Karbach, C Wahle, K Kairemo, T Alanko, ... Oncoimmunology 3 (10), e958937, 2014 | 64 | 2014 |
| Cell morphological profiling enables high-throughput screening for PROteolysis TArgeting Chimera (PROTAC) phenotypic signature MA Trapotsi, E Mouchet, G Williams, T Monteverde, K Juhani, R Turkki, ... ACS Chemical Biology 17 (7), 1733-1744, 2022 | 52 | 2022 |
| ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer T Pellinen, S Blom, S Sánchez, K Välimäki, JP Mpindi, H Azegrouz, ... Scientific Reports 8 (1), 2338, 2018 | 47 | 2018 |
| Cell Painting-based bioactivity prediction boosts high-throughput screening hit-rates and compound diversity J Fredin Haslum, CH Lardeau, J Karlsson, R Turkki, KJ Leuchowius, ... Nature Communications 15 (1), 3470, 2024 | 43 | 2024 |
| CDX2 loss with microsatellite stable phenotype predicts poor clinical outcome in stage II colorectal carcinoma K Slik, R Turkki, O Carpén, S Kurki, E Korkeila, J Sundström, T Pellinen The American journal of surgical pathology 43 (11), 1473-1482, 2019 | 43 | 2019 |
| Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients O Brück, MH Lee, R Turkki, I Uski, P Penttilä, L Paavolainen, P Kovanen, ... Modern Pathology 34 (12), 2229-2241, 2021 | 41 | 2021 |
Johan LundinMD, PhD, Research Director, FIMM, University of Helsinki and Professor, Karolinska InstitutetVerified email at helsinki.fi
